LUMISIGHT™ and Lumicell™ Direct Visualization System (DVS) offer 84% diagnostic accuracy in detecting residual cancer, in real-time, that may h...
Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® ...
-DoseMe, a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Au...
SimBioSys®, a leading TechBio company pioneering the fusion of spatial biophysics with artificial intelligence (AI) and computational modeling to redef...
-Hartwig Medical Foundation, a pioneer in deploying complete genomic profiling to improve oncology outcomes, and Ultima Genomics, a developer of a revoluti...
UroGen Pharma has initiated legal proceedings against pharmaceutical giant Teva over what they're dubbing as "Totally Mundane" Cancer Treatment Patents. Ur...
Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. have officially announced a definitive agreement for Genmab's acquisition of ProfoundBio in an all-cash dea...
Maverix Medical, a dedicated lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., announced the acquisition of Cirrus Bio for an ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Compr...
-Function Oncology, a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovativ...
The innovative partnership seeks to revolutionize decentralized genomic testing, offering swift turnaround times to identify individuals wh...
Telix Pharmaceuticals Limited (ASX: TLX) has announced a strategic agreement to partner with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaf...
AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a trailblazing clinical-stage biopharmaceutical company speciali...
The completion of Cohort 3 marks a significant milestone, with six participants receiving therapy with 67Cu-SAR-bisPSMA at the highest sing...
© 2024 Biopharma Boardroom. All Rights Reserved.
